JERUSALEM, April 18, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that its abstract, titled “Oral insulin may be effective in lowering hepatic insulin resistance and inflammation in patients with type 2 diabetes,” has been selected for poster presentation at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria.
